Vertex and Mirum: Biotech Investment Opportunities
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy MIRM?
Source: Fool
- Mirum Revenue Growth: Mirum has successfully commercialized Livmarli, achieving $521.3 million in revenue for 2025, a 54% increase, with Livmarli contributing $360 million, up 69%, indicating strong demand in the rare liver disease market, and forecasts sales of $630 million to $650 million in 2026, further solidifying its market position.
- Pipeline Potential: Mirum expects four potential registrational readouts over the next 18 months, particularly studies targeting chronic hepatitis delta virus; positive results could significantly expand its market coverage and enhance overall company valuation.
- Strategic Significance of Bluejay Acquisition: Mirum's $820 million acquisition of Bluejay Therapeutics adds brelovitug, which holds Breakthrough Therapy status, targeting HDV with no current approved therapies, potentially generating over $750 million in annual revenue and enhancing market competitiveness.
- Vertex Market Dominance: Vertex received FDA approval to expand the label for Trikafta and Alyftrek, covering 95% of U.S. cystic fibrosis patients, with 2025 revenue reaching $12 billion and expected growth to $12.95 billion to $13.1 billion in 2026, reinforcing its leadership in the biotech sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MIRM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MIRM
Wall Street analysts forecast MIRM stock price to rise
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 97.950
Low
81.00
Averages
102.33
High
140.00
Current: 97.950
Low
81.00
Averages
102.33
High
140.00
About MIRM
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States, Canada and Japan. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vertex and Mirum Pharmaceuticals Market Dynamics
- Vertex Financial Growth: Vertex Pharmaceuticals reported a record annual revenue of $12 billion in 2025, marking a 9% increase primarily driven by its dominance in cystic fibrosis (CF) therapies, with projected sales for 2026 expected to reach between $12.95 billion and $13.1 billion, solidifying its market leadership.
- Mirum Profitability Outlook: Mirum Pharmaceuticals achieved revenue of $521.3 million in 2025, a 54% increase, with Livmarli contributing $360 million, and forecasts for 2026 sales between $630 million and $650 million, indicating strong growth potential in the rare liver disease market.
- New Drug Development Progress: Mirum is conducting four potential registrational trials with key data expected over the next 18 months, and positive results could significantly expand its market reach, particularly in treating chronic hepatitis delta virus (HDV).
- Acquisition Strategy: Mirum completed its $820 million acquisition of Bluejay Therapeutics in January 2023 to enhance its pipeline with breakthrough therapies, which could generate over $750 million in annual revenue if successful, further strengthening its competitive position in the market.
See More
Vertex and Mirum: Biotech Investment Opportunities
- Mirum Revenue Growth: Mirum has successfully commercialized Livmarli, achieving $521.3 million in revenue for 2025, a 54% increase, with Livmarli contributing $360 million, up 69%, indicating strong demand in the rare liver disease market, and forecasts sales of $630 million to $650 million in 2026, further solidifying its market position.
- Pipeline Potential: Mirum expects four potential registrational readouts over the next 18 months, particularly studies targeting chronic hepatitis delta virus; positive results could significantly expand its market coverage and enhance overall company valuation.
- Strategic Significance of Bluejay Acquisition: Mirum's $820 million acquisition of Bluejay Therapeutics adds brelovitug, which holds Breakthrough Therapy status, targeting HDV with no current approved therapies, potentially generating over $750 million in annual revenue and enhancing market competitiveness.
- Vertex Market Dominance: Vertex received FDA approval to expand the label for Trikafta and Alyftrek, covering 95% of U.S. cystic fibrosis patients, with 2025 revenue reaching $12 billion and expected growth to $12.95 billion to $13.1 billion in 2026, reinforcing its leadership in the biotech sector.
See More
Mirum Pharmaceuticals: A Rising Star in Biotech
- Sales Growth: Mirum Pharmaceuticals experienced a 50% year-over-year increase in net product sales in Q4 2025, with Livmarli's sales soaring 69% to $360 million, indicating strong market demand in the rare disease treatment sector and enhancing financial stability.
- R&D Spending Plans: Although the company anticipates negative free cash flow in 2026, management aims to quickly return to positive cash flow by 2027, reflecting confidence in its future product pipeline and commitment to ongoing investment.
- Clinical Trial Progress: Mirum plans to report results from four pivotal clinical studies over the next 18 months, including Phase 3 data expected in Q2 2026, which could positively impact the stock price and further enhance market recognition of its potential.
- Market Valuation Potential: The peak sales estimates for Mirum's pipeline candidates exceed $4 billion, while the company's current market cap is around $5.8 billion; if its therapies succeed, Mirum could be valued at approximately $26 billion based on the average price-to-sales ratio of 6.4 in the biotech industry, indicating significant investment opportunities.
See More
Mirum Pharmaceuticals to Report Four Key Clinical Readouts in Next 18 Months
- Sales Growth: Mirum Pharmaceuticals experienced a 50% year-over-year increase in net product sales in Q4 2025, with Livmarli sales soaring 69% to $360 million, which enabled the company to generate positive free cash flow in 2025, indicating strong market demand and business sustainability.
- Clinical Trial Plans: The company plans to report four pivotal clinical study results over the next 18 months, including top-line data from a Phase 3 study evaluating volixibat for Primary Sclerosing Cholangitis expected in Q2 2026, which will significantly impact its future market performance.
- Market Potential Assessment: Peak sales estimates for Mirum's pipeline candidates exceed $4 billion, while the company's current market cap is around $5.8 billion; if its therapies succeed, Mirum could be valued at approximately $26 billion based on the average price-to-sales ratio of 6.4 in the biotech sector, highlighting its substantial growth potential.
- R&D Spending Impact: Although increased R&D spending will result in negative free cash flow this year, management expects to quickly return to positive free cash flow by 2027, reflecting confidence in its R&D pipeline and anticipated future profitability.
See More
ClearBridge SMID Cap Growth Strategy Outperforms Benchmark in Q1 2026
- Strong Performance: The ClearBridge SMID Cap Growth Strategy outperformed the Russell 2500 Growth Index in Q1 2026, indicating robust performance in small-cap investments that may attract more investor interest.
- New Portfolio Dynamics: During the first quarter, the fund initiated new positions in several companies, including Mirum Pharmaceuticals and Rambus, reflecting optimism about their future growth potential and possibly providing new profit opportunities for investors.
- Exit Strategy Adjustments: The fund exited positions in stocks like Matador Resources and Duolingo in Q1, demonstrating its keen market awareness and ability to flexibly adjust its portfolio to optimize returns.
- Selective Industry Strength: A small group of industrial stocks reached 52-week highs, indicating strong performance in specific sectors, which may present potential investment opportunities for investors, especially ahead of the upcoming Q1 earnings season.
See More
Mirum (MIRM) Q1 2025 Earnings Call Transcript
See More
Vertex and Mirum Pharmaceuticals Market Dynamics
- Vertex Financial Growth: Vertex Pharmaceuticals reported a record annual revenue of $12 billion in 2025, marking a 9% increase primarily driven by its dominance in cystic fibrosis (CF) therapies, with projected sales for 2026 expected to reach between $12.95 billion and $13.1 billion, solidifying its market leadership.
- Mirum Profitability Outlook: Mirum Pharmaceuticals achieved revenue of $521.3 million in 2025, a 54% increase, with Livmarli contributing $360 million, and forecasts for 2026 sales between $630 million and $650 million, indicating strong growth potential in the rare liver disease market.
- New Drug Development Progress: Mirum is conducting four potential registrational trials with key data expected over the next 18 months, and positive results could significantly expand its market reach, particularly in treating chronic hepatitis delta virus (HDV).
- Acquisition Strategy: Mirum completed its $820 million acquisition of Bluejay Therapeutics in January 2023 to enhance its pipeline with breakthrough therapies, which could generate over $750 million in annual revenue if successful, further strengthening its competitive position in the market.
See More
Vertex and Mirum: Biotech Investment Opportunities
- Mirum Revenue Growth: Mirum has successfully commercialized Livmarli, achieving $521.3 million in revenue for 2025, a 54% increase, with Livmarli contributing $360 million, up 69%, indicating strong demand in the rare liver disease market, and forecasts sales of $630 million to $650 million in 2026, further solidifying its market position.
- Pipeline Potential: Mirum expects four potential registrational readouts over the next 18 months, particularly studies targeting chronic hepatitis delta virus; positive results could significantly expand its market coverage and enhance overall company valuation.
- Strategic Significance of Bluejay Acquisition: Mirum's $820 million acquisition of Bluejay Therapeutics adds brelovitug, which holds Breakthrough Therapy status, targeting HDV with no current approved therapies, potentially generating over $750 million in annual revenue and enhancing market competitiveness.
- Vertex Market Dominance: Vertex received FDA approval to expand the label for Trikafta and Alyftrek, covering 95% of U.S. cystic fibrosis patients, with 2025 revenue reaching $12 billion and expected growth to $12.95 billion to $13.1 billion in 2026, reinforcing its leadership in the biotech sector.
See More
Mirum Pharmaceuticals: A Rising Star in Biotech
- Sales Growth: Mirum Pharmaceuticals experienced a 50% year-over-year increase in net product sales in Q4 2025, with Livmarli's sales soaring 69% to $360 million, indicating strong market demand in the rare disease treatment sector and enhancing financial stability.
- R&D Spending Plans: Although the company anticipates negative free cash flow in 2026, management aims to quickly return to positive cash flow by 2027, reflecting confidence in its future product pipeline and commitment to ongoing investment.
- Clinical Trial Progress: Mirum plans to report results from four pivotal clinical studies over the next 18 months, including Phase 3 data expected in Q2 2026, which could positively impact the stock price and further enhance market recognition of its potential.
- Market Valuation Potential: The peak sales estimates for Mirum's pipeline candidates exceed $4 billion, while the company's current market cap is around $5.8 billion; if its therapies succeed, Mirum could be valued at approximately $26 billion based on the average price-to-sales ratio of 6.4 in the biotech industry, indicating significant investment opportunities.
See More
Mirum Pharmaceuticals to Report Four Key Clinical Readouts in Next 18 Months
- Sales Growth: Mirum Pharmaceuticals experienced a 50% year-over-year increase in net product sales in Q4 2025, with Livmarli sales soaring 69% to $360 million, which enabled the company to generate positive free cash flow in 2025, indicating strong market demand and business sustainability.
- Clinical Trial Plans: The company plans to report four pivotal clinical study results over the next 18 months, including top-line data from a Phase 3 study evaluating volixibat for Primary Sclerosing Cholangitis expected in Q2 2026, which will significantly impact its future market performance.
- Market Potential Assessment: Peak sales estimates for Mirum's pipeline candidates exceed $4 billion, while the company's current market cap is around $5.8 billion; if its therapies succeed, Mirum could be valued at approximately $26 billion based on the average price-to-sales ratio of 6.4 in the biotech sector, highlighting its substantial growth potential.
- R&D Spending Impact: Although increased R&D spending will result in negative free cash flow this year, management expects to quickly return to positive free cash flow by 2027, reflecting confidence in its R&D pipeline and anticipated future profitability.
See More
ClearBridge SMID Cap Growth Strategy Outperforms Benchmark in Q1 2026
- Strong Performance: The ClearBridge SMID Cap Growth Strategy outperformed the Russell 2500 Growth Index in Q1 2026, indicating robust performance in small-cap investments that may attract more investor interest.
- New Portfolio Dynamics: During the first quarter, the fund initiated new positions in several companies, including Mirum Pharmaceuticals and Rambus, reflecting optimism about their future growth potential and possibly providing new profit opportunities for investors.
- Exit Strategy Adjustments: The fund exited positions in stocks like Matador Resources and Duolingo in Q1, demonstrating its keen market awareness and ability to flexibly adjust its portfolio to optimize returns.
- Selective Industry Strength: A small group of industrial stocks reached 52-week highs, indicating strong performance in specific sectors, which may present potential investment opportunities for investors, especially ahead of the upcoming Q1 earnings season.
See More
Mirum (MIRM) Q1 2025 Earnings Call Transcript
See More
